Zealand Pharma

Zealand Pharma is a biotechnology company that develops innovative peptide-based medicines. The company focuses on the discovery, design, and development of novel therapies, primarily addressing metabolic diseases such as obesity. Its core capability lies in leveraging peptide science to create solutions for unmet medical needs.

The company was founded in 1997 as Peptide Probe Technologies ApS by Bjarne Due Larsen, Lars Hellerung Christiansen, Leif Helth Jensen, Dan Buxbom, and Florian Schönharting. The original insight stemmed from the founders' belief in the significant potential of peptide chemistry for therapeutic drug development, with Dr. Bjarne Due Larsen being instrumental in pioneering related technologies.

Zealand Pharma's products are intended for individuals living with metabolic conditions and obesity, aiming to provide improved treatment options. The company’s long-term vision centers on advancing medicines that can profoundly impact metabolic health, striving to transform the future landscape of treatment for these widespread conditions.